• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Reports Third Quarter 2023 Results

    11/14/23 7:30:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Q3 Highlights

    • Total revenue of $30.7 million, up 5% year over year
    • Gross margin of 57%, compared to 58% for the prior year
    • Net income of $0.5 million, compared to net income of $1.2 million for the prior year
    • Adjusted EBITDA of $4.2 million, compared to $4.5 million for the prior year
    • Adjusted EPS of $0.07, compared to $0.09 for the prior year

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three and nine months ended September 30, 2023.

    "We delivered solid performance this quarter in spite of continued macroeconomic headwinds," said Scott Graeff, President and Chief Executive Officer of Luna. "We realized multiple significant wins in our Sensing business, providing further proof of the breadth of applications and abundance of opportunities for our fiber sensing solutions. We also recognized a particularly strong showing from our Communications Test business, where we saw significant increase in revenue after realizing moderate recovery from the headwinds this business faced last quarter."

    Third Quarter Fiscal 2023 Financial Summary

    Highlights of the financial results for the three months ended September 30, 2023 are:

     

     

    Three Months Ended September 30,

     

    Change

    (in thousands, except share and per share data)

     

     

    2023

     

     

     

    2022

     

     

     

    Revenue

     

    $

    30,703

     

     

    $

    29,153

     

     

    5

    %

     

     

     

     

     

     

     

    Gross profit

     

     

    17,629

     

     

     

    16,919

     

     

    4

    %

    Gross margin

     

     

    57

    %

     

     

    58

    %

     

     

     

     

     

     

     

     

    Operating expense

     

     

    16,477

     

     

     

    15,441

     

     

    7

    %

    Operating income

     

     

    1,152

     

     

     

    1,478

     

     

     

    Operating margin

     

     

    4

    %

     

     

    5

    %

     

     

     

     

     

     

     

     

    Other expense, net and income tax expense

     

     

    (691

    )

     

     

    (310

    )

     

     

     

     

     

     

     

     

     

    Net income from continuing operations

     

    $

    461

     

     

    $

    1,168

     

     

     

     

     

     

     

     

     

     

    Income from discontinued operations, net of tax of $— and $(78)

     

     

    —

     

     

     

    28

     

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    461

     

     

    $

    1,196

     

     

     

     

     

     

     

     

     

     

    Earnings per diluted share (EPS)

     

    $

    0.01

     

     

    $

    0.04

     

     

     

    Adjusted EPS

     

    $

    0.07

     

     

    $

    0.09

     

     

     

    Diluted weighted average shares outstanding

     

     

    35,218,547

     

     

     

    34,104,850

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    4,172

     

     

    $

    4,544

     

     

    (8

    )%

    A reconciliation of Adjusted EPS and Adjusted EBITDA to the nearest comparable figures under generally accepted accounting principles ("GAAP") can be found in the schedules included in this release.

    Revenue for the three months ended September 30, 2023 increased 5% compared to the prior-year period.

    Gross margin was 57% for the three months ended September 30, 2023, compared to 58% for the three months ended September 30, 2022, driven primarily by product mix. Operating income and margin were $1.2 million and 4% of total revenue, respectively, for the three months ended September 30, 2023, compared to an operating income of $1.5 million and 5% of total revenue, respectively, for the three months ended September 30, 2022.

    Net income was $0.5 million, or $0.01 per fully diluted share, for the three months ended September 30, 2023, compared to net income of $1.2 million, or $0.04 per fully diluted share, for the three months ended September 30, 2022. Adjusted EPS was $0.07 for the three months ended September 30, 2023 compared to $0.09 for the three months ended September 30, 2022.

    Adjusted EBITDA was $4.2 million for three months ended September 30, 2023, compared to $4.5 million for the three months ended September 30, 2022.

    Nine Months Ended Fiscal 2023 Financial Summary

    Highlights of the financial results for the nine months ended September 30, 2023 are:

     

     

    Nine Months Ended September 30,

     

    Change

    (in thousands, except share and per share data)

     

     

    2023

     

     

     

    2022

     

     

     

    Revenue

     

    $

    84,912

     

     

    $

    77,795

     

     

    9

    %

     

     

     

     

     

     

     

    Gross profit

     

     

    49,467

     

     

     

    47,162

     

     

    5

    %

    Gross margin

     

     

    58

    %

     

     

    61

    %

     

     

     

     

     

     

     

     

    Operating expense

     

     

    50,661

     

     

     

    50,510

     

     

    —

    %

    Operating loss

     

     

    (1,194

    )

     

     

    (3,348

    )

     

     

    Operating margin

     

     

    (1

    )%

     

     

    (4

    )%

     

     

     

     

     

     

     

     

    Other expense, net and income tax benefit

     

     

    (745

    )

     

     

    231

     

     

     

     

     

     

     

     

     

     

    Net loss from continuing operations

     

    $

    (1,939

    )

     

    $

    (3,117

    )

     

     

     

     

     

     

     

     

     

    Net (loss)/income from discontinued operations, net of income taxes of $(346) and $3,205

     

     

    (1,038

    )

     

     

    11,543

     

     

     

     

     

     

     

     

     

     

    Net (loss)/income

     

    $

    (2,977

    )

     

    $

    8,426

     

     

     

     

     

     

     

     

     

     

    (Loss)/earnings per diluted share (EPS)

     

    $

    (0.09

    )

     

    $

    0.26

     

     

     

    Adjusted EPS

     

    $

    0.11

     

     

    $

    0.12

     

     

    (8

    )%

    Diluted weighted average shares outstanding

     

     

    33,631,654

     

     

     

    32,492,276

     

     

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    7,759

     

     

    $

    7,450

     

     

    4

    %

    A reconciliation of Adjusted EPS and Adjusted EBITDA to the nearest comparable GAAP figures can be found in the schedules included in this release.

    Revenue for the nine months ended September 30, 2023 increased 9% compared to the prior-year period.

    Gross profit of $49.5 million for the nine months ended September 30, 2023 increased from $47.2 million for the nine months ended September 30, 2022 primarily due to higher sales. Operating loss and margin improved to $1.2 million and 1% of total revenue, respectively, for the nine months ended September 30, 2023, compared to $3.3 million and 4% of total revenue, respectively, for the nine months ended September 30, 2022.

    Net loss was $3.0 million, or $0.09 per fully diluted share, for the nine months ended September 30, 2023, compared to a net income of $8.4 million, or $0.26 per fully diluted share, for the nine months ended September 30, 2022, due to the gain on sale of Luna Labs. Adjusted EPS was $0.11 for the nine months ended September 30, 2023, compared to $0.12 for the nine months ended September 30, 2022.

    Adjusted EBITDA was $7.8 million for the nine months ended September 30, 2023, compared to $7.5 million for the nine months ended September 30, 2022.

    Q3 and Recent Business Highlights

    • Named George Gomez-Quintero as Chief Financial Officer
    • Awarded a multi-year service contract for system deployed on the largest fiber-optic monitoring solution ever installed
    • Secured multiple sales of seismic monitoring DAS instruments to American seismic labs and the U.S. government
    • Secured $1.5M+ in new orders for DAS and DTS systems for pipeline monitoring from the largest energy company in the UAE
    • Renewed global supply partnership agreement for infrastructure monitoring with one of the world's largest multinational conglomerates
    • Successfully deployed fiber optic-sensing based traffic monitoring for the Utah Department of Transportation

    2023 Full-Year Outlook

    Luna is updating the 2023 revenue outlook and maintaining the adjusted EBITDA outlook:

    • Total revenue of $120 million to $125 million for the full year 2023
    • Adjusted EBITDA of $14 million to $18 million for the full year 2023

    Luna is not providing an outlook for net income, which is the most directly comparable GAAP measure to Adjusted EBITDA, because changes in the items that Luna excludes from net income to calculate Adjusted EBITDA, such as share-based compensation, tax expense, and significant non-recurring charges, among other things, can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Luna's routine operating activities.

    The outlook above does not include any future acquisitions, divestitures, or unanticipated events.

    Non-GAAP Financial Measures

    In evaluating the operating performance of its business, Luna's management considers Adjusted EBITDA and Adjusted EPS, which are non-GAAP financial measures. Adjusted EBITDA and Adjusted EPS exclude certain charges and income that are required by GAAP. Adjusted EBITDA and Adjusted EPS provide useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Luna believes may not be indicative of its operating performance, because either they are unusual and Luna does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course.

    Adjusted EBITDA and Adjusted EPS should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Adjusted EBITDA and Adjusted EPS have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.

    Conference Call Information

    As previously announced, Luna will conduct an investor conference call at 8:30 am (ET) today, November 14, 2023, to discuss its financial results for the three and nine months ended September 30, 2023. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by telephone, the domestic dial-in number is 1.800.715.9871 .and the international dial-in number is.1.646.307.1963. Participants should ask to join the Luna Innovations Incorporated conference call, conference ID 6862329, and are advised to dial in at least fifteen minutes prior to the call. A replay of the conference call will be available on the company's website under "Webcasts and Presentations" for 30 days following the conference call.

    About Luna

    Luna Innovations Incorporated (www.lunainc.com) is a leader in optical technology, providing unique capabilities in high-performance, fiber optic-based, test products for the telecommunications industry and distributed fiber optic-based sensing for a multitude of industries. Luna's business model is designed to accelerate the process of bringing new and innovative technologies to market.

    Forward-Looking Statements

    The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include Luna's expectations regarding its projected full year 2023 financial results and outlook, and the Company's ability to secure additional significant wins. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of Luna may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include, without limitation, failure of demand for Luna's products and services to meet expectations, failure of target market to grow and expand, technological and strategic challenges, uncertainties related to the macroeconomic conditions and those risks and uncertainties set forth in Luna's Form 10-Q for the quarter ended September 30, 2023, and Luna's other periodic reports and filings with the Securities and Exchange Commission ("SEC"). Such filings are available on the SEC's website at www.sec.gov and on Luna's website at www.lunainc.com. The statements made in this release are based on information available to Luna as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

     
     

    Luna Innovations Incorporated

    Consolidated Balance Sheets (Unaudited)

    (in thousands, except share data)

     

     

    September 30, 2023

     

    December 31, 2022

     

    (unaudited)

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    6,028

     

     

    $

    6,024

     

    Accounts receivable, net

     

    39,304

     

     

     

    33,249

     

    Contract assets

     

    7,324

     

     

     

    7,691

     

    Inventory

     

    43,318

     

     

     

    36,582

     

    Prepaid expenses and other current assets

     

    4,207

     

     

     

    4,328

     

    Total current assets

     

    100,181

     

     

     

    87,874

     

    Property and equipment, net

     

    4,892

     

     

     

    4,893

     

    Intangible assets, net

     

    16,143

     

     

     

    18,750

     

    Goodwill

     

    26,896

     

     

     

    26,927

     

    Operating lease right-of-use assets

     

    7,999

     

     

     

    4,661

     

    Other non-current assets

     

    3,338

     

     

     

    3,255

     

    Deferred tax asset

     

    5,645

     

     

     

    4,647

     

    Total assets

    $

    165,094

     

     

    $

    151,007

     

    Liabilities and stockholders' equity

     

     

     

    Liabilities:

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt obligations

    $

    3,000

     

     

    $

    2,500

     

    Accounts payable

     

    10,617

     

     

     

    8,109

     

    Accrued and other current liabilities

     

    14,705

     

     

     

    16,694

     

    Contract liabilities

     

    4,619

     

     

     

    4,089

     

    Current portion of operating lease liabilities

     

    2,069

     

     

     

    2,239

     

    Total current liabilities

     

    35,010

     

     

     

    33,631

     

    Long-term debt obligations, net of current portion

     

    28,887

     

     

     

    20,726

     

    Long-term portion of operating lease liabilities

     

    6,178

     

     

     

    2,804

     

    Other long-term liabilities

     

    407

     

     

     

    444

     

    Total liabilities

     

    70,482

     

     

     

    57,605

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, par value $0.001, 100,000,000 shares authorized, 35,781,127 and 34,901,954 shares issued, 33,943,453 and 33,105,080 shares outstanding at September 30, 2023 and December 31, 2022, respectively

     

    36

     

     

     

    35

     

    Treasury stock at cost, 1,837,674 and 1,796,862 shares at September 30, 2023 and December 31, 2022, respectively

     

    (6,043

    )

     

     

    (5,607

    )

    Additional paid-in capital

     

    109,634

     

     

     

    104,893

     

    Accumulated deficit

     

    (5,273

    )

     

     

    (2,296

    )

    Accumulated other comprehensive loss

     

    (3,742

    )

     

     

    (3,623

    )

    Total stockholders' equity

     

    94,612

     

     

     

    93,402

     

    Total liabilities and stockholders' equity

    $

    165,094

     

     

    $

    151,007

     

     

    Luna Innovations Incorporated

    Consolidated Statements of Operations (Unaudited)

    (in thousands, except share and per share data)

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Revenue

    $

    30,703

     

     

    $

    29,153

     

     

    $

    84,912

     

     

    $

    77,795

     

    Cost of revenue

     

    13,074

     

     

     

    12,234

     

     

     

    35,445

     

     

     

    30,633

     

    Gross profit

     

    17,629

     

     

     

    16,919

     

     

     

    49,467

     

     

     

    47,162

     

    Operating expense:

     

     

     

     

     

     

     

    Selling, general and administrative

     

    12,829

     

     

     

    11,678

     

     

     

    39,565

     

     

     

    39,733

     

    Research, development and engineering

     

    2,719

     

     

     

    2,776

     

     

     

    8,257

     

     

     

    7,983

     

    Amortization of intangible assets

     

    929

     

     

     

    987

     

     

     

    2,839

     

     

     

    2,794

     

    Total operating expense

     

    16,477

     

     

     

    15,441

     

     

     

    50,661

     

     

     

    50,510

     

    Operating income/(loss)

     

    1,152

     

     

     

    1,478

     

     

     

    (1,194

    )

     

     

    (3,348

    )

    Other income/(expense):

     

     

     

     

     

     

     

    Other income

     

    115

     

     

     

    73

     

     

     

    98

     

     

     

    146

     

    Interest expense, net

     

    (613

    )

     

     

    (218

    )

     

     

    (1,566

    )

     

     

    (442

    )

    Total other expense, net

     

    (498

    )

     

     

    (145

    )

     

     

    (1,468

    )

     

     

    (296

    )

    Income/(loss) from continuing operations before income taxes

     

    654

     

     

     

    1,333

     

     

     

    (2,662

    )

     

     

    (3,644

    )

    Income tax expense/(benefit)

     

    193

     

     

     

    165

     

     

     

    (723

    )

     

     

    (527

    )

    Net income/(loss) from continuing operations

     

    461

     

     

     

    1,168

     

     

     

    (1,939

    )

     

     

    (3,117

    )

    Income/(loss) from discontinued operations, net of income tax expense/(benefit) of $—, $(78), $(346), and $3,205.

     

    —

     

     

     

    28

     

     

     

    (1,038

    )

     

     

    622

     

    Gain on sale of discontinued operations, net of tax of $3,117

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    10,921

     

    Net income/(loss) from discontinued operations

     

    —

     

     

     

    28

     

     

     

    (1,038

    )

     

     

    11,543

     

    Net income/(loss)

    $

    461

     

     

    $

    1,196

     

     

    $

    (2,977

    )

     

    $

    8,426

     

    Net income/(loss) per share from continuing operations:

     

     

     

     

     

     

     

    Basic

    $

    0.01

     

     

    $

    0.04

     

     

    $

    (0.06

    )

     

    $

    (0.10

    )

    Diluted

    $

    0.01

     

     

    $

    0.03

     

     

    $

    (0.06

    )

     

    $

    (0.10

    )

    Net income/(loss) per share from discontinued operations:

     

     

     

     

     

     

     

    Basic

    $

    —

     

     

    $

    —

     

     

    $

    (0.03

    )

     

    $

    0.36

     

    Diluted

    $

    —

     

     

    $

    —

     

     

    $

    (0.03

    )

     

    $

    0.36

     

    Net income/(loss) per share attributable to common stockholders:

     

     

     

     

     

     

     

    Basic

    $

    0.01

     

     

    $

    0.04

     

     

    $

    (0.09

    )

     

    $

    0.26

     

    Diluted

    $

    0.01

     

     

    $

    0.04

     

     

    $

    (0.09

    )

     

    $

    0.26

     

    Weighted average shares:

     

     

     

     

     

     

     

    Basic

     

    33,917,700

     

     

     

    32,800,690

     

     

     

    33,631,654

     

     

     

    32,492,276

     

    Diluted

     

    35,218,547

     

     

     

    34,104,850

     

     

     

    33,631,654

     

     

     

    32,492,276

     

     

    Luna Innovations Incorporated

    Consolidated Statements of Cash Flows (Unaudited)

    (in thousands)

     

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    Cash flows used in by operating activities

     

     

     

    Net (loss)/income

    $

    (2,977

    )

     

    $

    8,426

     

    Adjustments to reconcile net (loss)/income to net cash used in operating activities

     

     

     

    Depreciation and amortization

     

    4,092

     

     

     

    3,993

     

    Share-based compensation

     

    3,219

     

     

     

    3,204

     

    Loss on disposal of property and equipment

     

    281

     

     

     

    —

     

    Gain on sale of discontinued operations, net of tax

     

    —

     

     

     

    (10,921

    )

    Deferred taxes

     

    (998

    )

     

     

    (3,374

    )

    Change in assets and liabilities

     

     

     

    Accounts receivable

     

    (6,095

    )

     

     

    (6,166

    )

    Contract assets

     

    1,145

     

     

     

    (2,739

    )

    Inventory

     

    (6,520

    )

     

     

    (6,662

    )

    Other current assets

     

    202

     

     

     

    2,093

     

    Other non-current assets

     

    (121

    )

     

     

    599

     

    Accounts payable and accrued and other current liabilities

     

    (479

    )

     

     

    5,824

     

    Contract liabilities

     

    111

     

     

     

    2,425

     

    Other non-current liabilities

     

    —

     

     

     

    13

     

    Net cash used in operating activities

     

    (8,140

    )

     

     

    (3,285

    )

    Cash flows used in investing activities

     

     

     

    Acquisition of property and equipment

     

    (1,750

    )

     

     

    (2,313

    )

    Acquisition of intangible property

     

    (95

    )

     

     

    —

     

    Proceeds from sale of discontinued operations

     

    —

     

     

     

    12,973

     

    Acquisition of Luna Innovations Germany GmbH

     

    —

     

     

     

    (22,085

    )

    Other

     

    —

     

     

     

    29

     

    Net cash used in investing activities

     

    (1,845

    )

     

     

    (11,396

    )

    Cash flows provided by financing activities

     

     

     

    Payments on finance lease obligations

     

    (37

    )

     

     

    (36

    )

    Proceeds from borrowings under debt obligations

     

    10,400

     

     

     

    22,150

     

    Payments of debt obligations

     

    (1,750

    )

     

     

    (16,275

    )

    Repurchase of common stock

     

    (436

    )

     

     

    (294

    )

    Proceeds from ESPP

     

    546

     

     

     

    521

     

    Proceeds from the exercise of stock options

     

    1,272

     

     

     

    1,160

     

    Net cash provided by financing activities

     

    9,995

     

     

     

    7,226

     

    Effect of exchange rate changes on cash and cash equivalents

     

    (6

    )

     

     

    (1,784

    )

    Net increase/(decrease) in cash and cash equivalents

     

    4

     

     

     

    (9,239

    )

    Cash and cash equivalents—beginning of period

     

    6,024

     

     

     

    17,128

     

    Cash and cash equivalents—end of period

    $

    6,028

     

     

    $

    7,889

     

     

    Luna Innovations Incorporated

    Reconciliation of Net Income/(Loss) to EBITDA and Adjusted EBITDA

    (in thousands)

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

    2022

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Net income/(loss)

    $

    461

     

    $

    1,196

     

    $

    (2,977

    )

     

    $

    8,426

     

    Net income/(loss) from discontinued operations

     

    —

     

     

    28

     

     

    (1,038

    )

     

     

    11,543

     

    Net income/(loss) from continuing operations

     

    461

     

     

    1,168

     

     

    (1,939

    )

     

     

    (3,117

    )

    Interest expense, net

     

    613

     

     

    218

     

     

    1,566

     

     

     

    442

     

    Income tax expense/(benefit)

     

    193

     

     

    165

     

     

    (723

    )

     

     

    (527

    )

    Depreciation and amortization

     

    1,353

     

     

    1,299

     

     

    4,092

     

     

     

    3,993

     

    EBITDA

     

    2,620

     

     

    2,850

     

     

    2,996

     

     

     

    791

     

    Share-based compensation

     

    1,046

     

     

    1,027

     

     

    3,219

     

     

     

    3,027

     

    Integration and transaction expense

     

    59

     

     

    184

     

     

    308

     

     

     

    2,184

     

    Amortization of inventory step-up

     

    —

     

     

    134

     

     

    —

     

     

     

    391

     

    Other non-recurring charges (1)

     

    447

     

     

    349

     

     

    1,236

     

     

     

    1,057

     

    Adjusted EBITDA

    $

    4,172

     

    $

    4,544

     

    $

    7,759

     

     

    $

    7,450

     

     

     (1) - Other non-recurring charges primarily include facility consolidation/set-up costs and one-time insurance deductible.

     

    Luna Innovations Incorporated

    Reconciliation of Net Income/(Loss) to Adjusted EPS

    (in thousands, except per share data)

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Net income/(loss)

    $

    461

     

     

    $

    1,196

     

     

    $

    (2,977

    )

     

    $

    8,426

     

    Net income/(loss) from discontinued operations

     

    —

     

     

     

    28

     

     

     

    (1,038

    )

     

     

    11,543

     

    Net income/(loss) from continuing operations

     

    461

     

     

     

    1,168

     

     

     

    (1,939

    )

     

     

    (3,117

    )

    Share-based compensation

     

    1,046

     

     

     

    1,027

     

     

     

    3,219

     

     

     

    3,027

     

    Integration and transaction expense

     

    59

     

     

     

    184

     

     

     

    308

     

     

     

    2,184

     

    Amortization of intangible assets

     

    929

     

     

     

    988

     

     

     

    2,839

     

     

     

    2,793

     

    Amortization of inventory step-up

     

    —

     

     

     

    134

     

     

     

    —

     

     

     

    391

     

    Other non-recurring charges (1)

     

    447

     

     

     

    349

     

     

     

    1,236

     

     

     

    1,057

     

    Income tax effect on adjustments

     

    (620

    )

     

     

    (671

    )

     

     

    (1,901

    )

     

     

    (2,363

    )

    Adjusted income from continuing operations

    $

    2,322

     

     

    $

    3,179

     

     

    $

    3,762

     

     

    $

    3,972

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EPS

    $

    0.07

     

     

    $

    0.09

     

     

    $

    0.11

     

     

    $

    0.12

     

     

     

     

     

     

     

     

     

    Adjusted weighted average shares:

     

     

     

     

     

     

     

    Diluted

     

    35,219

     

     

     

    34,105

     

     

     

    33,632

     

     

     

    32,492

     

     

     (1) - Other non-recurring charges primarily include facility consolidation/set-up costs and one-time insurance deductible.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231114163191/en/

    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Stock to Be Suspended from Nasdaq Listing

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, due to the Company's inability to meet the March 27, 2025 deadline to file its previously disclosed delinquent filings with the Securities and Exchange Commission to regain compliance, the trading in its securities will be suspended tomorrow, January 7, 2025, and subsequently delisted from The Nasdaq Stock Market LLC ("Nasdaq"). Following the suspension, the Company expects its shares to be eligible to trade on the over-the-counter ("OTC") market, specifically the OTC Expert Market. The suspension/delisting of the Company's stock from Nasdaq does not

      1/6/25 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Financials

    Live finance-specific insights

    See more
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care